Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

IO Biotech, Inc. (IOBT)

2.82   0.03 (1.08%) 01-27 16:00
Open: 2.74 Pre. Close: 2.79
High: 2.87 Low: 2.74
Volume: 21,892 Market Cap: 81(M)

Technical analysis

as of: 2023-01-27 4:45:32 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.76     One year: 4.39
Support: Support1: 2.57    Support2: 2.17
Resistance: Resistance1: 3.22    Resistance2: 3.76
Pivot: 2.64
Moving Average: MA(5): 2.84     MA(20): 2.6
MA(100): 2.69     MA(250): 4.37
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 52.4     %D(3): 57.8
RSI: RSI(14): 55.7
52-week: High: 9.77  Low: 2.15
Average Vol(K): 3-Month: 84 (K)  10-Days: 171 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IOBT ] has closed below upper band by 27.8%. Bollinger Bands are 14.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.87 - 2.88 2.88 - 2.9
Low: 2.71 - 2.72 2.72 - 2.74
Close: 2.8 - 2.82 2.82 - 2.84

Company Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Headline News

Mon, 23 Jan 2023
2023-01-23 | NDAQ:IOBT | Press Release | IO Biotech Inc. - Stockhouse

Fri, 20 Jan 2023
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully - Simply Wall St

Thu, 19 Jan 2023
Internet of Battlefield Things (IoBT) Market 2023 In-depth Analysis by ... - Digital Journal

Mon, 09 Jan 2023
IO Biotech (IOBT) Provides Business Update -

Mon, 28 Nov 2022
Healthcare Stocks Moving Monday: AXSM, NUTX, KTRA, IOBT, CINC, TCBP, PKBO, ONCS - InvestorsObserver

Wed, 16 Nov 2022
Abdelzaher's IoBT REIGN Alliance Receives 5-year Extension Worth ... - Illinois Computer Science News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 29 (M)
Shares Float 4 (M)
% Held by Insiders 11.1 (%)
% Held by Institutions 82.6 (%)
Shares Short 11 (K)
Shares Short P.Month 32 (K)

Stock Financials

EPS -7.54
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.32
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -40.6
Return on Equity (ttm) -72.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -66 (M)
Levered Free Cash Flow -37 (M)

Stock Valuations

PE Ratio -0.38
PEG Ratio 0
Price to Book value 0.52
Price to Sales 0
Price to Cash Flow -1.23

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.